press_release_conclusion: Drop level from 10 percent risk to 4 percent to extend lives of more women, say researchers
abstract_conclusion: Conclusions Premenopausal RRSO appears to be extremely cost-effective at ≥4% lifetime OC risk, with ≥42.7 days gain in life expectancy if compliance with hormone replacement therapy is high.